You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Aurobindo Pharma slips on recalling products in US market

Capital Market 

Aurobindo Pharma fell 1.11% to Rs 724 after the drug maker confirmed the recall of 2,820 bottles of metroprolol tartrate tables in the US market.

The media reported that New Jersey-based Aurobindo Pharma USA Inc, a unit of Aurobindo Pharma, is recalling 2,820 bottles of metoprolol tartrate tablets "due to presence of foreign substance: product complaints received for the presence of metal wire in one tablet".

Metoprolol is used with or without other medications to treat high blood pressure (hypertension).

In its clarification to the bourses on 4 October 2021, Aurobindo Pharma confirmed the recall of 2,820 bottles of Metoprolol tartrate tablets in the US market. It added that the recall was done at the pharmacy level.

On a consolidated basis, Aurobindo Pharma's net profit fell 1.68% to Rs 769.97 crore on 2.46% rise in net sales to Rs 5,691.85 crore in Q1 FY22 over Q1 FY21.

Aurobindo Pharma headquartered at Hyderabad, India, develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, October 05 2021. 12:04 IST